BioCardia (BCDA) Projected to Post Earnings on Wednesday

BioCardia (NASDAQ:BCDA) is expected to be posting its Q1 2026 results after the market closes on Wednesday, May 13th. Analysts expect the company to announce earnings of ($0.17) per share for the quarter. Individuals can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Wednesday, May 13, 2026 at 4:30 PM ET.

BioCardia (NASDAQ:BCDA) last released its quarterly earnings results on Tuesday, March 24th. The company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.20) by $0.14. On average, analysts expect BioCardia to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

BioCardia Stock Down 2.7%

Shares of BCDA opened at $1.10 on Wednesday. The company has a market cap of $12.03 million, a PE ratio of -0.85 and a beta of 0.56. The business has a fifty day moving average of $1.20 and a 200 day moving average of $1.28. BioCardia has a 52-week low of $1.00 and a 52-week high of $2.92.

Institutional Investors Weigh In On BioCardia

Institutional investors and hedge funds have recently bought and sold shares of the company. DRW Securities LLC purchased a new stake in shares of BioCardia in the 4th quarter worth $72,000. Geode Capital Management LLC grew its holdings in BioCardia by 70.4% during the 4th quarter. Geode Capital Management LLC now owns 66,003 shares of the company’s stock worth $83,000 after acquiring an additional 27,263 shares in the last quarter. Finally, Cetera Investment Advisers bought a new position in BioCardia during the 2nd quarter worth about $40,000. 20.57% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of BioCardia in a research note on Monday, April 20th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, BioCardia has a consensus rating of “Hold” and an average price target of $25.00.

About BioCardia

BioCardia, Inc is a clinical-stage biotechnology company dedicated to developing novel cell-based therapies for patients with cardiovascular disease. The company’s core focus lies in advancing regenerative medicine approaches that address both chronic heart failure and acute myocardial infarction. BioCardia leverages proprietary delivery technologies to optimize the targeted administration of therapeutic cells directly into the heart muscle.

The company’s flagship products include the Helix Transendocardial Delivery System and the CardiAMP Cell Therapy System.